The global point of care infectious disease diagnostics market by Technology (Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), By Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health Disorders, and Others), By End User (Hospitals, Diagnostic Laboratories, Home-Care Settings, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1,764.6 million in 2016 and is projected to exhibit a CAGR of 14.5% over the forecast period (2017 – 2025). Point of care diagnostics are efficient in emerging economies of Asia Pacific wherein infectious diseases and especially tropical disease such as malaria are highly prevalent. Infectious point of care testing serves advantages such as increasing access to care in remote areas, time and cost efficiency, and rapid diagnosis, which can greatly affect treatment outcome. Infectious diseases such as HIV, tuberculosis, and malaria are prevalent in emerging economies such as Africa and Asia Pacific. For instance, according to the World Health Organization (WHO), an estimated 36.7 million people were suffering from HIV in 2016.
According to the World Health Organization (WHO), 2016, around 10.4 million people were affected with tuberculosis and an estimated 1 million pediatric population was affected with tuberculosis. Technological advancements to facilitate speedy diagnosis and extensive product portfolios of point of care infectious disease diagnostics offered by manufacturer’s supports the growth of Point of Care Infectious Disease Diagnostics Market. For instance, Becton Dickinson and Company launched point-of-care system BD FACSPresto in 2014 for HIV/AIDS patients. This CD4 counter system provides percentage results of CD4 T lymphocytes and hemoglobin concentration to stage and monitor HIV/AIDS patients. OraSure Technologies, Inc., announced prequalification of its OraQuick HIV Self-Test by the World Health Organization (WHO). This prequalification ensure that diagnostic tests severe diseases meet global standards of quality, safety, and efficacy.
Browse 40 Market Data Tables and 42 Figures spread through 145 Pages and in-depth TOC on Point of Care Infectious Disease Diagnostics Market by Technology (Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), By Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health Disorders, and Others), By End User (Hospitals, Diagnostic Laboratories, Home-Care Settings, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025
To know the latest trends and insights prevalent in the Point of Care Infectious Disease Diagnostics Market, click the link below:
Alere, Inc. launched first-ever rapid diagnostic test, Malaria Ag P.f, for detection of asymptomatic malaria infection in May 2017. Furthermore, Infectious Disease Research Institute (IDRI) developed a fusion antigen in January 2017, which is used as a part of diagnostic test manufactured by InBios International, Inc. for Chagas disease. Trinity Biotech plc received CE marking for Uni-Gold H. pylori Antigen point-of-care test in 2014. The Uni-Gold H. pylori Antigen is a 15 min rapid test, used to aid in the diagnosis of Helicobacter pylori (H. pylori) infection and to monitor the effectiveness of treatment. Furthermore, Cepheid received the U.S. Food & Drug Administration clearance and CLIA waiver for Xpert Xpress Flu test in January 2018. GenePOC announced CE marking of its revogene instrument in January 2017, and successfully combined the CE mark for the revogene instrument with two critical tests, GBS and C.diff. The company intends to build a menu of tests for infectious diseases, including hospital acquired infections.
Key Takeaways of the Point of Care Infectious Disease Diagnostics Market:
- The global point of care infectious disease diagnostics market is expected to exhibit a CAGR of 5% over the forecast period (2017 – 2025), owing to product launches by the key players such as Alere, Inc., and rising demand for rapid diagnostic tests
- Hospital associated infections (HAIs) is expected to exhibit strong growth and is expected to generate maximum revenue over the forecast period
- Hospitals end user segment is expected to generate maximum revenue over the forecast period due to high prevalence of hospital acquired infections, wherein, these test could be useful at the point of care along
- Asia Pacific is expected to witness staggering growth over the forecast period, owing to large customer base and high prevalence of infectious diseases such as malaria and tuberculosis
- Major players operating in the point of care infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Acon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc.
